Introduction {#sec1-1}
============

Lung cancer is one of the most common cancers and cause of cancer-related death all over the world. It accounts for 13% of all new cancer cases and 19% of cancer-related deaths worldwide.\[[@ref1]\]

Only 20%--30% of all lung cancer patients are operable at diagnosis and only 40%--50% of them can be resected for cure. Most patients presenting with lung cancer have a locally advanced or metastatic disease at the time of presentation and are managed with radiotherapy and/or chemotherapy.\[[@ref2]\] Nearly 30%--40% of these patients present with symptoms related to the endobronchial component, namely, cough, hemoptysis, shortness of breath, and postobstructive atelectasis with infection.\[[@ref3]\]

Efforts to relieve this obstructive process are worthwhile to improve the quality of life. Until recently, the most common technologies used in these situations were laser photoresection and cryotherapy. External beam irradiation, although effective, may not be possible because of the proximity of dose-limiting structures adjacent to the tracheobronchial tree (i.e., esophagus and spinal cord).\[[@ref4]\]

Brachytherapy is one of the most efficient methods in overcoming symptoms of endobronchial obstruction in the palliative treatment of tracheal and lung cancer with a significant improvement in the quality of life and performance status with acceptable toxicities.\[[@ref5][@ref6]\]

Cancer Research Institute, Dehradun, is the largest and single referral tertiary cancer center in the state of Uttarakhand, India. We present our experience of short-term clinical and endoscopic response and treatment-related acute toxicities in patients with malignant endobronchial tumors treated with high-dose-rate endobronchial brachytherapy (HDR-EB).

Materials and Methods {#sec1-2}
=====================

Patient selection {#sec2-1}
-----------------

This prospective study was conducted in the Department of Radiation Oncology, Cancer Research Institute, SRHU University, over a period of 12 months. Thirty patients with primary diagnosis of carcinoma lung and significant endobronchial component and symptoms, Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥2 were recruited after taking written informed consent and ethical clearance certificate from Institutional Ethics Committee. Exclusion criteria include informed consent not granted, impediments to bronchoscope catheter insertion, the presence of tracheoesophageal fistula, and bleeding disorders.

Speiser\'s scoring index was used for scoring the degree of endobronchial obstruction and the symptoms of hemoptysis, dyspnea, cough, and pneumonitis. The extent of tumor involvement was assessed by bronchoscopy and contrast-enhanced computed tomography chest.

Treatment {#sec2-2}
---------

EB was performed as an outpatient procedure. Transnasal fiberoptic bronchoscopy was performed to define the location and extent of tumor. Afterloading Lumincath applicator (a 6 French flexible nylon catheter) was introduced into the airway lumen and positioned at least 2 cm beyond to the visible tumor.

Brachytherapy planning was done with the help of Oncentra MasterPlan system. Computed tomography-based dose distribution was done with the aim of 95% of clinical target volume receive more than 90% of the prescribed dose \[[Figure 1](#F1){ref-type="fig"}\]. The target volume was described at a depth of 1 cm from the source axis. Brachytherapy was delivered at weeks 1, 2, and 3 at 7 Gy per se ssion using microselectron HDR remote afterloading unit (Nucletron) with an iridium-192 radioactive source \[[Figure 2](#F2){ref-type="fig"}\].

![Dose distribution of a treatment planning to main right bronchus lesion](SAJC-7-267-g001){#F1}

![Patient with a catheter in airway during treatment on high-dose-rate-microselectron](SAJC-7-267-g002){#F2}

All patients were evaluated clinically and with fiber-optic bronchoscopy 1 month after completion of therapy. Procedure and treatment-related toxicities were recorded. Radiation bronchitis was recorded using The Clinique Sainte Catherine grading system.

Data management and statistical analysis {#sec2-3}
----------------------------------------

Interpretation and analysis of obtained results were carried out using software SPSS version 20 (IBM, Armonk, NY, USA). Categorical variables are expressed as frequencies and percentages. Wilcoxon sign test was used to determine the significant change in cough, degree of obstruction, obstruction pneumonia, etc., pre and posttreatment. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

The median age was 62 years (range 42--75). The subjects were predominantly male with male:female = 14:1. Squamous cell carcinoma was the most predominant histology (63.3%). Cough and hemoptysis were the most common symptoms and were seen in 90% of patients. Summary of baseline patient characteristics is shown in [Table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics of patients

![](SAJC-7-267-g003)

Out of 30 patients, 25 patients were able to complete the treatment and were analyzed 1 month posttreatment. Two patients were expired and three were defaulted during treatment and were not included in the analyses.

On posttreatment response assessment, all the patients had significant symptomatic relief with a significant *P* value (\<0.001) for all the symptoms analyzed \[[Table 2](#T2){ref-type="table"}\]. Cough was improved in 95.6% of patients with complete resolution in 43.4% of patients. Complete response for dyspnea was seen in 30% of patients, whereas PR was seen in 65% of patients. Out of 23 patients presenting with hemoptysis, all of them have symptomatic relief posttreatment. Complete response was seen in 87% of patients and partial in 13% of patients. Sixteen patients presented with obstructive pneumonia and a complete response was seen in 12 patients, while partial in 3 patients.

###### 

Clinical and endoscopic results for the studied patients

![](SAJC-7-267-g004)

All the patients had obstruction of \>50% at presentation. Endoscopic response was seen in 21 patients, while 4 patients had no change in degree of obstruction. Fifteen (60%) patients had a reduction of \>50% of their endobronchial component \[[Table 2](#T2){ref-type="table"}\].

The treatment-related morbidity was low, and there were no serious acute complications. Radiation bronchitis was seen in 8 (32%) patients, and esophagitis was seen in 2 (8%) patients. One patient experienced bronchospasm during treatment and was managed with inhaled beta-2 agonists. No fatal complications such as fistula, massive hemoptysis, and pneumothorax occurred.

Discussion {#sec1-4}
==========

Most of the patients diagnosed with lung cancer have a locally advanced or metastatic disease at the time of presentation and are not candidate for definitive/curative treatment.\[[@ref7]\] Endobronchial obstruction and related symptoms worsen the quality of life in lung cancer patients. The most important consideration in these patients is to restore the patency of the airway.\[[@ref8][@ref9]\]

As a result, most of these patients are managed with palliative intent and various treatment options include laser therapy, external beam radiation therapy (EBRT), systemic therapy, and endobronchial brachytherapy (EBBT). Various studies have shown that EBBT is effective, safe, and convenient with limited toxicities as compared to other modalities. Although the advantages of this technique are well established in clinical practice, it lacks the benefit of robust randomized controlled trials. Many investigators have shown that patients treated with EBBT have a significant symptomatic response as well as improvement in performance status.\[[@ref10][@ref11]\]

As per literature, majority of the patients with endobronchial obstruction present with poor performance status. In our study, majority of the patients had an ECOG PS of 3 (66.7%). Similarly, Taulelle *et al*.\[[@ref12]\] and Celebioglu *et al*. in their studies showed that \>50% of patients had a poor performance status ≥2.\[[@ref13]\]

There is a lack of consensus regarding doses and fractionation schedules and different investigators had used different HDR-EB protocols.\[[@ref14]\] In the present study, patients were treated with HDR-EB with a dose of 7 Gy weekly for 3 weeks, which was close to the most effective fractionation scheme 7.5 Gy in three fractions once a week in the study done by Speiser and Spratling.\[[@ref15]\]

Kubaszewska *et al*. showed that, in patients with poor performance status, single fraction of 10--15 Gy can be used, which is cost sparing and more convenient. On the other hand, in patients with good performance status, weekly treatment enables to have a better local control and effectively relieves the symptoms of endobronchial obstructions.\[[@ref16]\]

All the patients had a good symptomatic relief in the presenting symptoms. Hemoptysis, cough, and dyspnea were improved in 100%, 95.6%, and 95% of patients, respectively. Symptomatic response for cough, dyspnea, and hemoptysis was seen in 88%, 75%, and 96%, respectively, with a significant *P* value (0.0001) in the analyses done by Escobar-Sacristán *et al*.\[[@ref17]\] Similar response rates were also seen in the large series done by Gollins *et al*.\[[@ref18]\] and Taulelle *et al*.\[[@ref12]\]

At 1 month posttreatment, endoscopic response was seen in 84% of patients with more than 50% reduction of their endobronchial component in 15 patients. Gustafson *et al*.\[[@ref4]\] reported that 64% of their patients had a 50% or greater reduction in the degree of obstruction.

In the present study, acute toxicities were reported in the form of radiation bronchitis (32% of patients), bronchospasm (4%), and esophagitis (8%).

The incidence of radiation bronchitis in the various studies reported in the literature is variable because of different HDR-EB protocols used as well as depending on whether used alone or with EBRT. In a study done by Anacak *et al*.,\[[@ref19]\] the rate of radiation bronchitis reached as high as 70%. Dagnault *et al*. in their study showed an incidence of 46% radiation bronchitis when HDR-EB is given as 5 Gy per week for four sessions.\[[@ref20]\]

Given these findings, we believe that HDR-EB can provide effective palliation and should be recommended in patients with a symptomatic endobronchial disease. For cost-sparing reasons, single dose treatment can be chosen in place of weekly repeated fractions.

Conclusion {#sec1-5}
==========

Our results support that HDR-EB is a highly effective, safe, convenient treatment for palliation of patients presenting with symptoms of endobronchial obstruction. The procedure was well tolerated with acceptable rate of complications and can be done as an outpatient procedure.
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